Next‐generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B‐cell precursor acute lymphoblastic leukaemia.

The article discusses the use of next-generation sequencing and high DNA input to detect measurable residual disease (MRD) in the peripheral blood of patients with B-cell precursor acute lymphoblastic leukemia (ALL). Traditional MRD assessment in bone marrow samples may miss MRD in peripheral blood, but modern molecular methods can enhance detection. The study found that adjusting traditional MRD assessment strategies can improve MRD detection in peripheral blood, but it may not fully replace bone marrow monitoring. The findings suggest that high DNA input and next-generation sequencing can increase the sensitivity of MRD detection in peripheral blood, especially in cases where bone marrow samples are unavailable. [Extracted from the article]